rate of recurrence after primary pterygium removal Number of participants with adverse events as a measure of safety and tolerability pterygium recurrent pterygium bevacizumab VEGF anti-
Conditions
Interventions
bevacizumab eye drop 0.05% will apply 4 times a day for 3 months,normal saline eye drop 0.9% will apply 4 times a day for 3 months.
Experimental Drug,Placebo Comparator No treatment
bevacizumab eye drop,placebo normal saline eye drop
Sponsors
Chulalongkorn university
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: * Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.) * Patients with pterygium who understand and can follow the study protocol. * Patients of age more than 30 years
Exclusion criteria
Exclusion criteria: * Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing. * Patients who are pregnancy or lactation. * Patients who have a history of allergy to bevacizumab. * Patients who have a history of allergy to steroid eye drops
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rate of recurrence after primary pterygium removal 3 months pterygium grading | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety and tolerability 3 months observation and eye examination | — |
Countries
Thailand
Contacts
Public ContactNgamjit Kasetsuwan
Department of Ophthalmology, Faculty of medicine
Outcome results
None listed